Scholarlink

Background <p>There is substantial unexplained variability in the development of disease. A genetic risk score for COPD identifies individuals at markedly elevated risk of COPD; however, many high-genetic risk individuals do not develop disease. We sought to define genetic resilience in COPD by identifying and characterizing individuals who are resistant to their elevated genetic susceptibility.</p> Methods <p>We defined resilience to genetic risk (genetic resilience) as absence of airflow obstruction (FEV<sub>1</sub>/FVC <i>≥</i> 0.70) in individuals with cigarette smoking exposure with a polygenic risk score for COPD at the 90th percentile or above. We defined clinical resilience according to previously published criteria, including a low symptom burden, limited radiographic disease, and normal lung-function decline despite similar smoking history. Using data from the Genetic Epidemiology of COPD (COPDGene) study, we compared genetically resilient individuals to clinically resilient individuals and genetic risk-matched individuals with COPD on clinical characteristics, radiographic findings, longitudinal outcomes, mortality, biomarkers, and social determinants of health.</p> Results <p>We found that, after adjustment for covariates, genetically resilient individuals (<i>n</i> = 144) had better lung function (β = 35.9% predicted, <i>p</i> &lt; 0.001), fewer symptoms, and less radiographic disease compared to genetic risk-matched individuals with COPD (<i>n</i> = 362). Conversely, when compared to clinically resilient individuals (<i>n</i> = 420), genetically resilient individuals had slightly lower lung function and slightly worse radiographic measures of disease. Both clinically and genetically resilient individuals had higher survival compared to genetic-risk matched cases (hazard ratios = 0.34 and 0.41 with <i>p</i> &lt; 0.001 and <i>p</i> = 0.002, respectively). While the majority of genetically resilient individuals remained resilient across the 5-year and 10-year follow-up visits, a higher proportion of clinically resilient individuals remained resilient across the follow-up period. Non-Hispanic white genetically resilient individuals had higher social vulnerability across multiple measures compared to both clinically resilient individuals and genetic risk-matched individuals with COPD.</p> Discussion <p>Genetic resilience to COPD represents a unique subtype of smokers that is distinct from clinical resilience and has important disease-related differences from genetic risk-matched individuals with COPD. Future studies are needed to identify the underlying biological contributors to the multiple types of resilience in COPD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Genetic resilience to chronic obstructive pulmonary disease is a clinically distinct subtype in individuals with cigarette smoke exposure

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月28日

查看全文
  • Auyon J. Ghosh,
  • Ko-Yun Chang,
  • Matthew Moll,
  • Jonathan Hess,
  • Liam P. Coyne,
  • Sanchit Panda,
  • Michael H. Cho,
  • Russell P. Bowler,
  • Stephen J. Glatt,
  • Craig P. Hersh

摘要

Background

There is substantial unexplained variability in the development of disease. A genetic risk score for COPD identifies individuals at markedly elevated risk of COPD; however, many high-genetic risk individuals do not develop disease. We sought to define genetic resilience in COPD by identifying and characterizing individuals who are resistant to their elevated genetic susceptibility.

Methods

We defined resilience to genetic risk (genetic resilience) as absence of airflow obstruction (FEV1/FVC ≥ 0.70) in individuals with cigarette smoking exposure with a polygenic risk score for COPD at the 90th percentile or above. We defined clinical resilience according to previously published criteria, including a low symptom burden, limited radiographic disease, and normal lung-function decline despite similar smoking history. Using data from the Genetic Epidemiology of COPD (COPDGene) study, we compared genetically resilient individuals to clinically resilient individuals and genetic risk-matched individuals with COPD on clinical characteristics, radiographic findings, longitudinal outcomes, mortality, biomarkers, and social determinants of health.

Results

We found that, after adjustment for covariates, genetically resilient individuals (n = 144) had better lung function (β = 35.9% predicted, p < 0.001), fewer symptoms, and less radiographic disease compared to genetic risk-matched individuals with COPD (n = 362). Conversely, when compared to clinically resilient individuals (n = 420), genetically resilient individuals had slightly lower lung function and slightly worse radiographic measures of disease. Both clinically and genetically resilient individuals had higher survival compared to genetic-risk matched cases (hazard ratios = 0.34 and 0.41 with p < 0.001 and p = 0.002, respectively). While the majority of genetically resilient individuals remained resilient across the 5-year and 10-year follow-up visits, a higher proportion of clinically resilient individuals remained resilient across the follow-up period. Non-Hispanic white genetically resilient individuals had higher social vulnerability across multiple measures compared to both clinically resilient individuals and genetic risk-matched individuals with COPD.

Discussion

Genetic resilience to COPD represents a unique subtype of smokers that is distinct from clinical resilience and has important disease-related differences from genetic risk-matched individuals with COPD. Future studies are needed to identify the underlying biological contributors to the multiple types of resilience in COPD.